Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151

Showing 26-50 of 151 citing articles:

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
Yanguo Shang, M. Pang, Shengnan Fu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117391-117391
Closed Access | Times Cited: 1
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
Victor Hugo Fonseca de Jesus, Maria Cecília Mathias-Machado, João Paulo Fogacci de Farias, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5015-5015
Open Access | Times Cited: 17
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5079-5079
Open Access | Times Cited: 16
Precision Oncology: 2023 in Review
Yonina R. Murciano‐Goroff, Sarah P. Suehnholz, Alexander Drilon, et al.
Cancer Discovery (2023) Vol. 13, Iss. 12, pp. 2525-2531
Open Access | Times Cited: 16
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Robin A. Jansen, Sara Mainardi, Matheus Henrique Dias, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 9
Open Access | Times Cited: 6
Targeting RAF dimers in RAS mutant tumors: From biology to clinic
Huanhuan Yin, Qiulin Tang, Hongwei Xia, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 5, pp. 1895-1923
Open Access | Times Cited: 6
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Elena Brozos-Vázquez, Marta Toledano‐Fonseca, Nicolás Costa‐Fraga, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102719-102719
Open Access | Times Cited: 6
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
Birgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Cancer Discovery (2024) Vol. 15, Iss. 1, pp. 119-138
Open Access | Times Cited: 6
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Judit Moldvay, József Tı́már
Pathology & Oncology Research (2024) Vol. 29
Open Access | Times Cited: 5
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
Szu-Aun Long, Amber M. Amparo, Grace Goodhart, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Danielle Brazel, Misako Nagasaka
Targeted Oncology (2024) Vol. 19, Iss. 3, pp. 297-301
Open Access | Times Cited: 5
Top advances of the year: Targeted therapy for lung cancer
Maisam Makarem, Pasi A. Jänne
Cancer (2024) Vol. 130, Iss. 19, pp. 3239-3250
Closed Access | Times Cited: 5
Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian
Viviana Cortiana, Rabab Hunaid Abbas, Harshal Chorya, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2329-2329
Open Access | Times Cited: 5
Advances in Personalized Oncology
Hiba Mechahougui, James Gutmans, Gina Colarusso, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2862-2862
Open Access | Times Cited: 5
The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation
Xiang Li, Sen Tian, Hui Shi, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 5, pp. 687-697
Open Access | Times Cited: 4
NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity
Duo Xu, Shiyuan Yin, Yongqian Shu
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer
Yongfeng Shang, Shengnan Fu, M. Pang, et al.
(2025)
Closed Access
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
Tuan Hoang, Erica S. Tsang
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access

Scroll to top